Literaturverzeichnis 2017 / 2018
Hier finden Sie die Literaturangaben zu den Übersichtsartikeln der Zeitschrift für Infektionstherapie aus den Jahren 2017
und 2018
Reihenfolge:
Heft 6 / 2018
Heft 5 / 2018
Heft 4 / 2018
Heft 3 / 2018
Heft 2 / 2018
Heft 1 / 2018
Heft 6 / 2017
Heft 3 / 2017
Heft 2 / 2017
Heft 1 / 2017
Literaturangaben zum Übersichtsartikel aus
Heft 6 / 2018 der Zeitschrift für Infektionstherapie
Impfungen im Alter
1. Esposito S et al.. Vaccination of 50+ adults to promote healthy ageing in Europe: The way forward. Vaccine. 2018 Sep
18;36(39):5819-5824.
2. Wagner A et al. Age-related differences in humoral and cellular immune responses after primary immunisation: indications for
stratified vaccination schedules. Sci Rep. 2018 Jun 29;8(1):9825
3. Agarwal D, Schmader KE, Kossenkov AV, Doyle S, Kurupati R, Ertl HCJ. Immune response to influenza
vaccination in the elderly is altered by chronic medication use. Immun Ageing. 2018 Aug 31;15:19 FREE FULL TEXT
4. Centers for Disease Control and Prevention (CDC). Interim adjusted estimates of seasonal influenza vaccine effectiveness -
United States, February 2013. MMWR Morb Mortal Wkly Rep. 2013 Feb 22;62(7):119-23 FREE FULL TEXT
5. Lode HM, Stahlmann R. [Vaccinations in respiratory medicine]. HNO. 2015 Sep;63(9):649-59
6. STIKO Neuerungen in den Empfehlungen der Ständigen
Impfkommission (STIKO) beim RKI für 2018/2019 Epid Bull 2018; 383-386 PDF-DATEI
7. Wutzler P, Hardt R, Knuf M, Wahle K. Targeted vaccine selection in influenza vaccination. Dtsch Arztebl Int. 2013 Nov
22;110(47):793-8 FREE FULL TEXT
8. Grohskopf LA, Sokolow LZ, Broder KR, Walter EB, Fry AM, Jernigan DB. Prevention and Control of Seasonal Influenza with
Vaccines: Recommendations of the Advisory Committee on Immunization Practices-United States, 2018-19 Influenza Season. MMWR Recomm Rep. 2018 Aug 24;67(3):1-20 FREE FULL
TEXT
9. Pica N, Palese P. Toward a universal influenza virus vaccine: prospects and challenges. Annu Rev Med. 2013;64:189-202
Review
10. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax.
2012 Jan;67(1):71-9 Review
11. Pletz MW et al. The Burden of Pneumococcal Pneumonia – Experience of the German Competence Network CAPNETZ.
Pneumologie 2012; 66(08): 470-475
12. Ewig S, Birkner N, Strauss R, Schaefer E, Pauletzki J, Bischoff H, Schraeder P, Welte T, Hoeffken G. New perspectives on
community-acquired pneumonia in 388 406 ???? patients. Results from a nationwide mandatory performance measurement programme in healthcare quality. Thorax. 2009 Dec;64(12):1062-9
FREE FULL TEXT
13. Imöhl M, van der Linden M. [Invasive pneumococcal disease in Germany in the era of pneumococcal conjugate vaccination]. Dtsch
Med Wochenschr. 2014 Jun;139(25-26):1346-51
14. STIKO, Wissenschaftliche Begründung für die Aktualisierung der
Pneumokokken-Impfempfehlung für Senioren Epidem Bull 2016;36:351-383 PDF-DATEI
15. Empfehlungen der Sächsischen Impfkommission zur Durchführung von Schutzimpfungen im Freistaat Sachsen vom 02.09.1993; Stand: 01.01.2018 (PDF)
16. Ewig S et al. [Management of Adult
Community-acquired Pneumonia and Prevention - Update 2016]. Pneumologie. 2016 Mar;70(3):151-200
17. Durando P, Faust SN, Fletcher M, Krizova P, Torres A, Welte T. Experience with
pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults. Clin Microbiol Infect. 2013 Oct;19 Suppl 1:1-9 Review FREE FULL TEXT
18. Clutterbuck EA et al. Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B
cells. J Infect Dis. 2012 May 1;205(9):1408-16 FREE FULL TEXT
19. Farmaki PF, Chini MC, Mangafas NM, Tzanoudaki MT, Piperi CP, Lazanas MZ, Spoulou VS. Immunogenicity and Immunological Memory
Induced by the 13-Valent Pneumococcal Conjugate Followed by the 23-Valent Polysaccharide Vaccine in HIV-Infected Adults. J Infect Dis. 2018 Jun 5;218(1):26-34
20. Fätkenheuer G, Kwetkat A, Pletz MW, Schelling J, Schulz RJ, van der Linden M, Welte T. [Prevention in the elderly: position
paper on pneumococcal vaccinations. Results of an expert workshop on 15 November 2013 in Cologne, Germany]. Z Gerontol Geriatr. 2014 Jun;47(4):302-9
21. Bonten MJ et al. Polysaccharide
conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015 Mar 19;372(12):1114-25 FREE FULL TEXT
22. Kobayashi M, Bennett NM, Gierke R, Almendares O, Moore MR, Whitney CG, Pilishvili T. Intervals Between PCV13 and PPSV23
Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2015 Sep 4;64(34):944-7 FREE FULL TEXT
23. Riffelmann M, Wirsing von König CH. [Lifelong protection against pertussis]. Dtsch Med Wochenschr. 2009 Apr;134 Suppl
2:S86-9
24. Zimmermann U, Gavazzi G, Richard P, Eymin C, Soubeyrand B, Baudin M. Immunogenicity and safety of a booster dose of
diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (Tdap-IPV; Repevax) administered concomitantly versus non-concomitantly with an influenza vaccine (Vaxigrip) to
adults aged ≥60 years: an open-label, randomised trial. Vaccine. 2013 Mar 1;31(11):1496-502
25. Tseng HF et al. Vaccine Safety Datalink (VSD) Team. Safety of a tetanus-diphtheria-acellular pertussis vaccine when used
off-label in an elderly population. Clin Infect Dis. 2013 Feb;56(3):315-21
26. Esposito S et al. Recommended immunization schedules for adults: Clinical practice guidelines by the Escmid Vaccine Study
Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid). Hum Vaccin Immunother. 2016 Jul 2;12(7):1777-94
FREE FULL TEXT
27. STIKO Empfehlungen der Ständigen Impfkommission (STIKO) beim Robert Koch-Institut –
2018/2019. Epidem Bull 2018;34:335-382 PDF-DATEI
28. Arvin A. Aging, immunity, and the varicella-zoster virus. N Engl J Med. 2005;352:2266-7
29. Wutzler P. [Herpes zoster and postherpetic neuralgia - prevention by vaccination?]. Dtsch Med Wochenschr. 2009 Apr;134 Suppl
2:S90-4
30. Dooling KL et al. Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines. MMWR Morb
Mortal Wkly Rep. 2018 Jan 26;67(3):103-108 FREE FULL TEXT
Literaturangaben zum Übersichtsartikel aus
Heft 5 / 2018 der Zeitschrift für Infektionstherapie
Harnwegsinfektionen beim Mann - welche
Antibiotika und wie lange behandeln?
1. Schaeffer AJ, Nicolle LE.
Urinary Tract Infections in Older Men. N Engl J Med. 2016 Feb 11;374(6):562-71 Review.
2. Ulleryd P et al. Prostatic
involvement in men with febrile urinary tract infection as measured by serum prostate-specific antigen and transrectal ultrasonography. BJU Int. 1999 Sep;84(4):470-4
3. Wagenlehner
FM, Umeh O, Steenbergen J, Yuan G, Darouiche RO. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised,
double-blind, phase 3 trial (ASPECT-cUTI). Lancet. 2015;385:1949-56
4. Wagenlehner FM, Sobel JD,
Newell P, Armstrong J, Huang X, Stone GG, Yates K, Gasink LB. Ceftazidime-avibactam versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis:
RECAPTURE, a Phase 3 Randomized Trial Program. Clin Infect Dis. 2016 Sep 15;63(6):754-762.
FREE FULL TEXT
5. Shirley M.
Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections. Drugs. 2018 Apr;78(6):675-692
6. Ulleryd P, Sandberg T.
Ciprofloxacin for 2 or 4 weeks in the treatment of febrile urinary tract infection in men: a randomized trial with a 1 year follow-up. Scand J Infect Dis. 2003;35(1):34-9
7. Drekonja DM et al. Urinary tract
infection in male veterans: treatment patterns and outcomes. JAMA Intern Med. 2013 Jan 14;173(1):62-8
8. Peterson J, Kaul S, Khashab
M, Fisher AC, Kahn JB. A double-blind, randomized comparison of levofloxacin 750 mg once-daily for five days with ciprofloxacin 400/500 mg twice-daily for 10 days for the treatment of complicated
urinary tract infections and acute pyelonephritis. Urology. 2008 Jan;71(1):17-22
9. Mospan GA, Wargo KA. 5-Day
versus 10-Day Course of Fluoroquinolones in Outpatient Males with a Urinary Tract Infection (UTI). J Am Board Fam Med. 2016 11/12;29(6):654-662
10. van Nieuwkoop C et al.
Treatment duration of febrile urinary tract infection: a pragmatic randomized, double-blind, placebo-controlled non-inferiority trial in men and women. BMC Med. 2017 Apr 3;15(1):70 FREE
FULL TEXT
Literaturangaben zum Übersichtsartikel aus
Heft 4 / 2018 der Zeitschrift für Infektionstherapie
Antibiotika in der Zahnmedizin
1. Schwabe U et al.
Arzneiverordnungs-Report 2015,
Springer Verlag Stuttgart 2016
2. Schwabe U et
al.
Arzneiverordnungs-Report 2016,
Springer Verlag Stuttgart 2017
3. Abu-Ta'a M, Quirynen M, Teughels W, van Steenberghe D. Asepsis during periodontal surgery involving oral implants and the
usefulness of peri-operative antibiotics: a prospective, randomized, controlled clinical trial. J Clin Periodontol. 2008 Jan;35(1):58-63
4. Podbielski A, Pahncke D, Mittelmeier W. [Antibiotic prophylaxis for patients with joint prostheses undergoing dental
treatment--a topic for discussion]. Z Orthop Unfall. 2009 May-Jun;147(3):350-5
5. Limeres Posse J, Álvarez Fernández M, Fernández Feijoo J, Medina Henríquez J, Lockhart PB, Chu VH, Diz Dios P. Intravenous
amoxicillin/clavulanate for the prevention of bacteraemia following dental procedures: a randomized clinical trial. J Antimicrob Chemother. 2016 Jul;71(7):2022-30
6. Darouiche RO. Antimicrobial approaches for preventing infections associated with surgical implants. Clin Infect Dis. 2003 May
15;36(10):1284-9
7. López-Píriz R, Aguilar L, Giménez MJ. Management of odontogenic infection of pulpal and periodontal origin. Med Oral Patol Oral
Cir Bucal. 2007 Mar 1;12(2):E154-9
8. Aravena PC, Oyarzún CP, Arias MF, Monardes H, Jerez A, Benso B. Single-Dose Bioavailability for Prophylactic Coverage in
Patients Undergoing Dental Implant Surgery. Int J Oral Maxillofac Implants. 2018 Mar/Apr;33(2):419-424
9. Binahmed A, Stoykewych A, Peterson L. Single preoperative dose versus long-term prophylactic antibiotic regimens in dental
implant surgery. Int J Oral Maxillofac Implants. 2005 Jan-Feb;20(1):115-7
10. Esposito M, Grusovin MG, Loli V, Coulthard P, Worthington HV. Does antibiotic prophylaxis at implant placement decrease early
implant failures? A Cochrane systematic review. Eur J Oral Implantol. 2010 Summer;3(2):101-10
11. Ahmad N, Saad N. Effects of antibiotics on dental implants: a review. J Clin Med Res. 2012 Feb;4(1):1-6. FREE
FULL TEXT
12. Arduino PG, Tirone F, Schiorlin E, Esposito M. Single preoperative dose of prophylactic amoxicillin versus a 2-day
postoperative course in dental implant surgery: A two-centre randomised controlled trial. Eur J Oral Implantol. 2015 Summer;8(2):143-9
13. Surapaneni H, Yalamanchili PS, Basha MH, Potluri S, Elisetti N, Kiran Kumar MV. Antibiotics in dental implants: A review of
literature. J Pharm Bioallied Sci. 2016 Oct;8(Suppl 1):S28-S31. Review. FREE FULL TEXT
14. Richey R, Wray D, Stokes T; Guideline Development Group. Prophylaxis against infective endocarditis: summary of NICE guidance.
BMJ. 2008 Apr 5;336(7647):770-1 FREE FULL TEXT
15. Dayer MJ, Jones S, Prendergast B, Baddour LM, Lockhart PB, Thornhill MH. Incidence of infective endocarditis in England,
2000-13: a secular trend, interrupted time-series analysis. Lancet. 2015 Mar 28;385(9974):1219-28 FREE FULL TEXT
16. Tubiana S, Blotière PO, Hoen B, Lesclous P, Millot S, Rudant J, Weill A, Coste J, Alla F, Duval X. Dental procedures,
antibiotic prophylaxis, and endocarditis among people with prosthetic heart valves: nationwide population based cohort and a case crossover study. BMJ. 2017 Sep 7;358:j3776 FREE FULL
TEXT
17. Habib G. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective
Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J. 2015
Nov 21;36(44):3075-3128
18. Rademacher WMH, Walenkamp GHIM, Moojen DJF, Hendriks JGE, Goedendorp TA, Rozema FR. Antibiotic prophylaxis is not indicated
prior to dental procedures for prevention of periprosthetic joint infections. Acta Orthop. 2017 Oct;88(5):568-574 FREE FULL TEXT
19. Rostetter C, Schenkel J, Rücker M, Lübbers HT. Amoxicillin mit Clavulansäure. Standardantibiotikum im allgemeinzahnärztlichen
Alltag. Swiss Dent J. 2017;127(7-8):654-655
20. Thornhill MH, Dayer MJ, Prendergast B, Baddour LM, Jones S, Lockhart PB. Incidence and nature of adverse reactions to
antibiotics used as endocarditis prophylaxis. J Antimicrob Chemother. 2015 Aug;70(8):2382-8 FREE FULL TEXT
Literaturangaben zum Übersichtsartikel aus
Heft 3 / 2018 der Zeitschrift für Infektionstherapie
Proteinbindung von Antibiotika -
inaktivierende und antibakterielle Wirkungen
1. Davis BD. Binding of sulfonamides by plasma proteins. Science
1942;95:78
2. Merrikin DJ, Briant J, Rolinson GN. Effect of protein binding on antibiotic activity in vivo. J Antimicrob Chemother. 1983 Mar;11(3):233-8
3. Dalhoff A. Seventy-Five Years of Research on Protein Binding. Antimicrob Agents Chemother 2018;62. pii: e01663-17.
4. Silverman JA, Mortin LI, Vanpraagh AD et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 2005; 191:
2149–2152
Literaturangaben zum Übersichtsartikel aus
Heft 1 / 2018 der Zeitschrift für Infektionstherapie
1. Theuretzbacher U. Antibiotic
innovation for future public health needs. Clin Microbiol Infect. 2017 Oct;23(10):713-717.
2. O'Dwyer K et al. Bacterial
resistance to leucyl-tRNA synthetase inhibitor GSK2251052 develops during treatment of complicated urinary tract infections. Antimicrob Agents Chemother. 2015 Jan;59(1):289-98 FREE FULL TEXT
3. Tacconelli E et al. Discovery,
research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Inf Dis 2017 (online, 21. Dezember 2017) PubMed abstract
4. Wright H, Bonomo RA, Paterson
DL. New agents for the treatment of infections with Gram-negative bacteria: restoring the miracle or false dawn? Clin Microbiol Infect. 2017 Oct;23(10):704-712 PubMed abstract
5. Torres A et al.
Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Lancet Inf Dis 2017
(15. Dezember 2017, online) PubMed abstract
6. Hackel MA, Lomovskaya O,
Dudley MN, Karlowsky JA, Sahm DF. In Vitro Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae. Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii:
e01904-17 PubMed abstract
7. Ito A et al. In Vitro
Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria. Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01454-17 FREE FULL TEXT
8. Tillotson GS. Trojan Horse
Antibiotics-A Novel Way to Circumvent Gram-Negative Bacterial Resistance? Infect Dis (Auckl). 2016 Oct 11;9:45-52. FREE FULL TEXT
Literaturangaben zum Übersichtsartikel aus
Heft 6 / 2017 der Zeitschrift für Infektionstherapie
1: Quon BS, Goss CH, Ramsey BW. Inhaled antibiotics for lower airway infections. Ann Am
Thorac Soc. 2014 Mar;11(3):425-34 FREE FULL TEXT
2: Ramsey BW, Pepe MS, Quan JM et al. Intermittent administration of inhaled tobramycin in
patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med. 1999 Jan 7;340(1):23-30 FREE FULL TEXT
3: Wenzler E, Fraidenburg DR, Scardina T, Danziger LH. Inhaled Antibiotics for
Gram-Negative Respiratory Infections. Clin Microbiol Rev. 2016 Jul;29(3):581-632 FREE FULL TEXT
4: Bassetti M, Luyt CE, Nicolau DP, Pugin J. Characteristics of an ideal nebulized
antibiotic for the treatment of pneumonia in the intubated patient. Ann Intensive Care. 2016 Dec;6(1):35 FREE FULL TEXT
5: Moskowitz SM, Foster JM, Emerson J, Burns JL. Clinically feasible biofilm susceptibility
assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol. 2004 May;42(5):1915-22 FREE FULL TEXT
6: Niederman MS, Chastre J, Corkery K, Fink JB, Luyt CE, García MS. BAY41-6551 achieves
bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia. Intensive Care Med. 2012 Feb;38(2):263-71
7: Brodt AM, Stovold E, Zhang L. Inhaled antibiotics for stable non-cystic fibrosis
bronchiectasis: a systematic review. Eur Respir J. 2014 Aug;44(2):382-93 FREE FULL TEXT
8: Barker AF, Couch L, Fiel SB, Gotfried MH, Ilowite J, Meyer KC, O'Donnell A, Sahn SA,
Smith LJ, Stewart JO, Abuan T, Tully H, Van Dalfsen J, Wells CD, Quan J. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med.
2000 Aug;162(2 Pt 1):481-5
9: Haworth CS, Foweraker JE, Wilkinson P, Kenyon RF, Bilton D. Inhaled colistin in patients
with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med. 2014 Apr 15;189(8):975-82 FREE FULL TEXT
10: Serisier DJ, Bilton D, De Soyza A, Thompson PJ, Kolbe J, Greville HW, Cipolla D,
Bruinenberg P, Gonda I; ORBIT-2 investigators. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial.
Thorax. 2013 Sep;68(9):812-7 FREE FULL TEXT
11: Insmed, Inc. TR02-107 trialreport.
Available from: www.insmed.com/pdf/Pub9%209_13_09.pdf
12: Wilson R, Welte T, Polverino E, De Soyza A, Greville H, O'Donnell A, Alder J, Reimnitz
P, Hampel B. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur Respir J. 2013 May;41(5):1107-15 FREE FULL TEXT
13: De Soyza A et al. Late-Breaking-Abstract: Respire I Europ Respir J 2016; 48,
Suppl 60
14: Aradigm Corporation: Memorandum July 27, 2017
15: Kollef MH, Micek ST. Recommendations for aerosolized antibiotics in
ventilator-associated pneumonia and ventilator-associated tracheobronchitis: too little and too late? Clin Microbiol Infect. 2017 Sep;23(9):593-595
16: Solé-Lleonart C, Rouby JJ, Blot S, Poulakou G, Chastre J, Palmer LB, Bassetti M, Luyt
CE, Pereira JM, Riera J, Felton T, Dhanani J, Welte T, Garcia-Alamino JM, Roberts JA, Rello J. Nebulization of Antiinfective Agents in Invasively Mechanically Ventilated Adults: A Systematic Review
and Meta-analysis. Anesthesiology. 2017 May;126(5):890-908
17: Rello J, Rouby JJ, Sole-Lleonart C, Chastre J, Blot S, Luyt CE, Riera J, Vos MC,
Monsel A, Dhanani J, Roberts JA. Key considerations on nebulization of antimicrobial agents to mechanically ventilated patients. Clin Microbiol Infect. 2017 Sep;23(9):640-646
18: Kollef M H et al. Chest 2017, in press
19: Niederman MS(1), Chastre J, Corkery K, Fink JB, Luyt CE, García MS.BAY41-6551 achieves
bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia. Intensive Care Med. 2012 Feb;38(2):263-71
20: Rello J, Solé-Lleonart C, Rouby JJ, Chastre J, Blot S, Poulakou G, Luyt CE, Riera J,
Palmer LB, Pereira JM, Felton T, Dhanani J, Bassetti M, Welte T, Roberts JA. Use of nebulized antimicrobials for the treatment of respiratory infections in invasively mechanically ventilated adults:
a position paper from the European Society of Clinical Microbiology and Infectious Diseases. Clin Microbiol Infect. 2017 Sep;23(9):629-639
Literaturangaben zum Übersichtsartikel aus
Heft 3 / 2017 der Zeitschrift für Infektionstherapie
Therapie von Helicobacter pylori-Infektionen
1. Warren JR Helicobacter: the ease and difficulty
of a new discovery (Nobel lecture). ChemMedChem. 2006;1:672-85
2. Hentschel E et al. Effect of
ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med. 1993;328:308-12 FREE FULL TEXT
3. Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG
Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017 Feb;112(2):212-239
4. Fischbach W S2k-Leitllinie Helicobacter pylori und
gastroduodenale Ulkuskrankheit. Z Gastroenterol. 2016 Apr;54(4):327-63
5. Wüppenhorst N et al. Prospective multicentre
study on antimicrobial resistance of Helicobacter pylori in Germany. J Antimicrob Chemother. 2014;69:3127-33
6. Regnath T, Raecke O, Enninger A, Ignatius R.
Increasing metronidazole and rifampicin resistance of Helicobacter pylori isolates obtained from children and adolescents between 2002 and 2015 in southwest Germany. Helicobacter.
2017;22:e12327
7. Best LM et al. Multilaboratory comparison of
proficiencies in susceptibility testing of Helicobacter pylori and correlation between agar dilution and E test methods. Antimicrob Agents Chemother. 2003 Oct;47(10):3138-44 FREE FULL
TEXT
8. Malfertheiner P et al. . Helicobacter pylori
eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label,
non-inferiority, phase 3 trial. Lancet. 2011 Mar 12;377(9769):905-13
9. Greenberg ER et al. 14-day triple, 5-day
concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet. 2011 Aug 6;378(9790):507-14 FREE FULL
TEXT
10. Marin AC, Nyssen OP, McNicholl AG, Gisbert JP.
Efficacy and Safety of Quinolone-Containing Rescue Therapies After the Failure of Non-Bismuth Quadruple Treatments for Helicobacter pylori Eradication: Systematic Review and Meta-Analysis. Drugs.
2017 May;77(7):765-776
Literaturangaben zum Übersichtsartikel aus
Heft 2 / 2017 der Zeitschrift für Infektionstherapie
Antiinfektive Therapie der Sepsis
1:
Seymour CW, Liu VX, Iwashyna TJ et al. Assessment of Clinical Criteria for Sepsis: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016 Feb
23;315(8):762-74
2:
Rhodes A, Evans LE, Alhazzani W et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Crit Care Med. 2017 Mar;45(3):486-552
3: Panknin HT, Müller-Werdan U, Schröder S. Neue Sepsisdefinition. ProCare. 2016
Oct;21(8):22-5
4:
Zhang D, Micek ST, Kollef MH. Time to Appropriate Antibiotic Therapy Is an Independent Determinant of Postinfection ICU and Hospital Lengths of Stay in Patients With Sepsis. Crit Care Med. 2015
Oct;43(10):2133-40
5:
Pletz MW, Bloos F, Burkhardt O et al. Pharmacokinetics of moxifloxacin in
patients with severe sepsis or septic shock. Intensive Care Med. 2010 Jun;36(6):979-83
6:
van Zanten AR, Polderman KH, van Geijlswijk IM, van der Meer GY, Schouten MA, Girbes AR. Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study. J Crit Care. 2008 Sep;23(3):422-30
7:
Roberts JA, Abdul-Aziz MH, Davis JS, Dulhunty JM, Cotta MO, Myburgh J, Bellomo R, Lipman J. Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis. A Meta-analysis of Individual Patient
Data from Randomized Trials. Am J Respir Crit Care Med. 2016 Sep 15;194(6):681-91
8:
Alejandria MM, Lansang MA, Dans LF, Mantaring JB 3rd. Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database Syst Rev. 2013 Sep
16;(9):CD001090
Literaturangaben zum Übersichtsartikel aus
Heft 1 / 2017 der Zeitschrift für Infektionstherapie
Optimale Dauer der Antibiotikatherapie – eine aktuelle Bestandsaufnahme
Druckversion 